Holen Sie sich die Stockscreener-App
220.91
2.51%
5.40
Schlusskurs vom Vortag:
$215.51
Offen:
$217.82
24-Stunden-Volumen:
1.13M
Relative Volume:
1.25
Marktkapitalisierung:
$10.87B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
27.58
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
+9.13%
1M Leistung:
+18.78%
6M Leistung:
+38.96%
1J Leistung:
+17.56%
1-Tages-Spanne:
$216.88
$222.37
1-Wochen-Bereich:
$194.93
$222.37
52-Wochen-Spanne:
$91.86
$222.37
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Vergleichen Sie CRL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
220.91 | 10.61B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
618.86 | 227.87B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
238.37 | 165.99B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
713.35 | 56.89B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
148.52 | 41.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
242.41 | 41.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-17 | Hochstufung | Argus | Hold → Buy |
| 2025-11-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Is Now An Opportune Moment To Examine Charles River Laboratories International, Inc. (NYSE:CRL)? - simplywall.st
Charles River Laboratories (CRL) Announces Leadership Transition - GuruFocus
Charles River Laboratories announces CEO transition, Girshick to succeed Foster - Investing.com UK
Charles River Labs Announces CEO Succession and Leadership Changes - TipRanks
Charles River Labs (CRL) plans CEO succession and new board role for Foster - Stock Titan
What Makes Charles River Laboratories (CRL) an Investment Bet? - MSN
Why Charles River Laboratories International Inc. stock stays resilientJuly 2025 Rallies & Reliable Trade Execution Plans - ulpravda.ru
Precision Trading with Charles River Laboratories International Inc. (CRL) Risk Zones - Stock Traders Daily
How Charles River Laboratories International Inc. stock compares to growth peersJuly 2025 Final Week & Community Consensus Trade Signals - ulpravda.ru
Will Charles River Laboratories International Inc. stock gain from lower inflationNew Guidance & Daily Chart Pattern Signal Reports - ulpravda.ru
Charles River Labs CEO to retire after more than three decades - NBC Boston
Charles River Laboratories Names Birgit Girshick CEO - citybiz
Charles River Laboratories appoints Birgit Girshick as CEO following James Foster's retirement - MSN
Can Charles River Laboratories International Inc. stock reach $100 price target2025 Market Outlook & AI Driven Price Predictions - ulpravda.ru
Charles River Laboratories International, Inc. Announces Chief Executive Officer Changes - MarketScreener
What catalysts could drive Charles River Laboratories International Inc. stock higherMarket Movement Recap & Expert Verified Stock Movement Alerts - ulpravda.ru
Charles River Labs CEO to retire in 2026 after 30+ years at the helm - The Business Journals
Why Charles River Laboratories International Inc. stock is favored by pension funds2025 Technical Patterns & Weekly High Return Forecasts - ulpravda.ru
Charles River Laboratories International, Chair, President, CEO James Foster to Retire - MarketScreener
Charles River Laboratories announces planned retirement of James C. Foster - MarketScreener
Charles River CEO Jim Foster to retire in May 2026 after 50-year career - Investing.com Canada
Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan - Business Wire
Portfolio Recap: Is Charles River Laboratories International Inc RV6 stock a top pick for value investorsMarket Risk Analysis & High Accuracy Trade Alerts - moha.gov.vn
Charles River Laboratories International, Inc. (CRL) Hit a 52 Week High, Can the Run Continue? - sharewise.com
What Makes Charles River (CRL) a New Buy Stock - Yahoo Finance
Charles River Laboratories stock hits 52-week high at $205.55 By Investing.com - Investing.com Nigeria
Charles River Laboratories International Insiders Placed Bullish Bets Worth US$1.25m - Yahoo Finance
Charles River Laboratories International (NYSE:CRL) Hits New 1-Year HighHere's Why - MarketBeat
Charles River Laboratories stock hits 52-week high at $205.55 - Investing.com India
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call Transcript - MSN
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Allspring Global Investments Holdings LLC Sells 113,185 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International, Inc. $CRL Shares Purchased by Boston Trust Walden Corp - MarketBeat
Charles River Laboratories Stock Tests Investor Patience as Biopharma Recalibrates - AD HOC NEWS
Charles River Laboratories International (NYSE:CRL) Reaches New 52-Week HighTime to Buy? - MarketBeat
Charles River Laboratories International, Inc. $CRL Stake Cut by Norris Perne & French LLP MI - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Charles River Laboratories International Earnings Notes - Trefis
Risk Report: Why analysts raise outlook for Charles River Laboratories International Inc. stockRecession Risk & AI Forecast for Swing Trade Picks - moha.gov.vn
Animal Model Market Strategic Insights, Industry Trends, Size, - openPR.com
Corient Private Wealth LLC Raises Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International (NYSE:CRL) Shares Gap UpHere's What Happened - MarketBeat
Backbone of Discovery: A Deep Dive into Charles River Laboratories (CRL) - FinancialContent
Charles River Laboratories (CRL): Valuation Check After SEC Clearance and BofA Upgrade Lift the Stock - simplywall.st
Contact Us – Inside INdiana BusinessBackbone of Discovery: A Deep Dive into Charles River Laboratories (CRL) - FinancialContent
Upslope Capital Management Sold Charles River (CRL) Due to Thesis Break - MSN
Is Charles River Laboratories stock underperforming the Dow? - MSN
Why Charles River Laboratories (CRL) Stock Is Trading Up Today - FinancialContent
Charles River Laboratories International (NYSE:CRL) Hits New 52-Week HighTime to Buy? - MarketBeat
Charles River Laboratories stock hits 52-week high at $200.96 - Investing.com
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):